European Commission Approves Single-Vial, Fully Liquid Menveo® Vaccine for Protection Against Meningococcal Disease

GSK plc (LSE/NYSE: GSK) announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of Menveo (Meningococca...

November 28, 2024 | Thursday | News
Novartis Announces European Commission Approval of Kisqali® (ribociclib) for Adjuvant Treatment of High-Risk HR+/HER2- Early Breast Cancer

Novartis announced that the European Commission (EC) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the ad...

November 28, 2024 | Thursday | News
West China Lecheng Hospital Launches Vorasidenib, First-in-Class Targeted Therapy for IDH-Mutant Glioma

It was announced that West China Lecheng Hospital has successfully introduced Vorasidenib for treatment at clinical practices, and the treatment began at o...

November 25, 2024 | Monday | News
Hanmi Pharmaceutical Showcases Promising Clinical Progress of BH3120 at SITC 2024 Conference

The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical...

November 25, 2024 | Monday | News
Halozyme Withdraws €2.0 Billion Acquisition Proposal for Evotec Amid Lack of Engagement

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: ...

November 25, 2024 | Monday | News
GSK’s Arexvy RSV Vaccine Approved in Japan for Adults Aged 50-59 at Increased Risk

GSK plc (LSE/NYSE: GSK) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indi...

November 25, 2024 | Monday | News
HUTCHMED and Takeda Launch FRUZAQLA® for Colorectal Cancer in Japan

Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — Milestone payment to be made to HUTCHMED fro...

November 22, 2024 | Friday | News
Abzena Expands Analytical Capabilities with GMP Cell-Based Potency Assays at Cambridge and San Diego Facilities

" Abzena, a leading CDMO/CRO, now offers GMP cell-based potency assays at its UK and US sites, enhancing its support for complex biologics and ADC programs...

November 20, 2024 | Wednesday | News
Ardena Secures Full GMP Approval for Expanded Nanomedicine Facility in Oss, Netherlands

" Ardena, a leading CDMO, has received full GMP approval for its advanced nanomedicine facility in Oss. This €20 million investment, featuring state...

November 20, 2024 | Wednesday | News
AstraZeneca’s Tagrisso (osimertinib) Recommended for EU Approval in Unresectable EGFR-Mutated Lung Cancer

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with ...

November 19, 2024 | Tuesday | News
Eli Lilly Announces Positive Phase 2 Results for Muvalaplin, Oral Treatment for Elevated Lp(a) Levels and Heart Disease Risk

Eli Lilly and Company (NYSE: LLY) announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhi...

November 19, 2024 | Tuesday | News
European Commission Approves OPUVIZ™ (SB15), a Biosimilar to Eylea, for Treatment of Retinal Disorders

Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has approved OPUVIZ™ 40 mg/mL solution...

November 19, 2024 | Tuesday | News
Tirzepatide Significantly Reduces Heart Failure Risk in Obese Patients with Preserved Ejection Fraction, New Data Show

Eli Lilly and Company (NYSE: LLY) announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk of worsening ...

November 18, 2024 | Monday | News
EMA Committee Recommends Approval of Opdivo® + Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

 Bristol Myers Squibb (NYSE: BMY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

November 18, 2024 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close